Molecular Insight Announces Resignation of Chief Medical Officer


Cambridge, MA, October 19, 2010 - Molecular Insight Pharmaceuticals (NASDAQ: MIPI) today announced that Norman D. LaFrance, M.D., has notified the Company of his resignation as Senior Vice President and Chief Medical Officer, effective November 5, 2010.

"During his years with Molecular Insight, Dr. LaFrance drew on his considerable expertise in pharmaceutical research and development to make significant contributions to the advancement of our product pipeline," said Daniel L. Peters, President and CEO. "We are grateful for Dr. LaFrance's efforts and wish him well in his future endeavors."

About Molecular Insight Pharmaceuticals, Inc.

Molecular Insight Pharmaceuticals is a clinical-stage biopharmaceutical company and pioneer in molecular medicine. The Company is focused on the discovery and development of targeted therapeutic and imaging radiopharmaceuticals for use in oncology. Molecular Insight has five clinical-stage candidates in development. For further information on Molecular Insight Pharmaceuticals, please visit www.molecularinsight.com.

Contacts:
Investors
Charles H. Abdalian
Senior Vice President of Finance
Chief Financial Officer
(617) 871-6618
cabdalian@molecularinsight.com

Media
Martin A. Reynolds
Manager
Corporate Communications
(617) 871-6734
mreynolds@molecularinsight.com

Susan Pietropaolo,
BCC Partners,
(201) 923-2049,
spietropaolo@bccpartners.com

More from Cleaning Products & Equipment

All Topics